These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 606429)

  • 1. Hyperparathyroidism and the predictability of response to 1alpha-hydroxyvitamin D3.
    Bone JM
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():83s-84s. PubMed ID: 606429
    [No Abstract]   [Full Text] [Related]  

  • 2. Bone disease and hyperparathyroidism in chronic renal failure: the effect of 1alpha-hydroxyvitamin D3.
    Peacock M; Aaron JE; Walker GS; Davison AM
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():73s-81s. PubMed ID: 606428
    [No Abstract]   [Full Text] [Related]  

  • 3. Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3.
    Madsen S
    Acta Med Scand Suppl; 1980; 638():3-120. PubMed ID: 6929650
    [No Abstract]   [Full Text] [Related]  

  • 4. The use of 1,25-dihydroxyvitamin D3 in early renal failure.
    Goodman WG; Coburn JW
    Annu Rev Med; 1992; 43():227-37. PubMed ID: 1580587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment with 1-alpha hydroxy vitamin D3 of bone disease in hemodialysis. Therapeutic results and complications].
    García de Vinuesa S; Barril G; Luño J; Alles A; Jofré R; Pérez García R; Olivas E; López Gómez JM; Valderrábano F
    Rev Clin Esp; 1980 Dec; 159(5):317-22. PubMed ID: 7221095
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of alfacalcidol on renal bone disease in mild to moderate renal failure. Questions remain over alfacalcidol's efficacy in preventing secondary hyperparathyroidism.
    Fournier A; Esper NE; Moriniere P; Oprisiu R; Marie A
    BMJ; 1995 Jul; 311(6997):124; author reply 124-5. PubMed ID: 7677873
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
    Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
    Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of 1alpha-hydroxyvitamin D3 on calcium and mineral content of bone in renal osteodystrophy.
    Junor BJ; Catto GR
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():131s-138s. PubMed ID: 606411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone histomorphometry in patients with chronic renal failure: effect of 1alpha-hydroxyvitamin D3.
    Melsen F; Nielsen HE; Christensen MS
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():39s-44s. PubMed ID: 606423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone disease in children with chronic renal failure: therapy with 1alpha-hydroxyvitamin D3.
    Postlethwaite RJ; Houston IB
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():117s-124s. PubMed ID: 304772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1,25-dihydroxycholecalciferol. Effect on skeletal lesions and plasma parathyroid hormone levels in uremic osteodystrophy.
    Brickman AS; Sherrard DJ; Jowsey J; Singer FR; Baylink DJ; Maloney N; Massry SG; Norman AW; Coburn JW
    Arch Intern Med; 1974 Nov; 134(5):883-8. PubMed ID: 4613310
    [No Abstract]   [Full Text] [Related]  

  • 12. [1 alpha-hydroxycholecalciferol in treatment of renal osteodystrophy].
    Chalmers TM; Davie MW; Hunter JO; Szaz KF
    J Urol Nephrol (Paris); 1974 Dec; 80(12):981. PubMed ID: 4617778
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of 1alpha-hydroxyvitamin D3 in pre-dialysis renal bone disease.
    Pierides AM; Ellis HA; Simpson W; Cook D; Kerr DN
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():109s-116s. PubMed ID: 606409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1alpha-Hydroxycholecalciferol in children with renal osteodystrophy.
    Postlethwaite RJ; Houston IB
    Calcif Tissue Res; 1977 May; 22 Suppl():371-5. PubMed ID: 912549
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevention of renal osteodystrophy in predialysis patients.
    Sanchez CP; Goodman WG; Salusky IB
    Am J Med Sci; 1999 Jun; 317(6):398-404. PubMed ID: 10372840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in vitamin D metabolism as they pertain to chronic renal disease.
    Coburn JW; Hartenbower DL; Brickman AS
    Am J Clin Nutr; 1976 Nov; 29(11):1283-99. PubMed ID: 187055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spinal calcium changes with 1alpha-hydroxyvitamin D3.
    Dabek JT; Robinson BH; Naik RB; Al-Hiti K
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():147s-150s. PubMed ID: 606412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing the response to 1alpha-hydroxyvitamin D3 in patients with renal bone disease.
    Kanis JA; Russell RG; Naik RB; Earnshaw M; Smith R; Heynen G; Woods CG
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():51s-57s. PubMed ID: 606425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cessation of bone loss in chronic renal failure by 1-alpha-hydroxyvitamin D3: a controlled trial.
    Madsen S; Olgaard K; Ladefoged J
    Proc Eur Dial Transplant Assoc; 1978; 15():517-23. PubMed ID: 311003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anomalies of phosphorus-calcium metabolism in renal insufficiency. Value of the physiopathological diagnosis and therapy].
    Hioco D; Dorfmann H; Chot ST; Bordier P; de Zèze S
    Rev Rhum Mal Osteoartic; 1972 Oct; 39(10):617-25. PubMed ID: 5083698
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.